Latest Health News
Parkinson’s Breakthrough: Dopamine Acts as 'Oil' Not 'Gas Pedal' for Movement
A McGill University study reveals dopamine enables smooth movement like engine oil rather than controlling speed, reshaping Parkinson's understanding. Manipulating dopamine during mouse movements had no effect, but restoring baseline levels improved function, suggesting levodopa works by stabilizing levels. This could lead to targeted therapies maintaining steady dopamine, affecting over 110,000 Canadians with Parkinson's.
New Tool RNACOREX Uncovers Hidden Genetic Networks in Cancer
Spanish researchers developed RNACOREX, an open-source tool analyzing thousands of molecular interactions to reveal gene communication in cancer. It helps identify networks driving tumor growth, aiding personalized treatments. Released December 21, 2025, it promises to accelerate cancer research globally.
Hidden T Cell 'Spring' Motion Boosts Cancer Immunotherapy Potential
Scientists discovered T cell receptors activate via a novel spring-like motion, explaining immunotherapy variability across cancers. This breakthrough, from December 18, 2025, could enhance treatments for more patients by targeting this mechanism. It builds on prior T cell research for broader efficacy.
Influenza Cases Surge in Syria, H3N2 Dominant per Ministry of Health
Syria reports increasing influenza incidence, primarily H3N2, prompting health alerts as of December 20, 2025. Schoolchildren are notably affected in earlier waves, with ongoing monitoring. ProMED tracks this as a key emerging threat in the region.
Measles Outbreak in Northeastern Uganda Claims Lives
Uganda faces a fatal measles outbreak in northeastern districts as of December 19, 2025. Multiple cases confirmed, highlighting vaccination gaps amid regional instability. ProMED urges rapid response to contain spread.
FDA Approves Rucaparib for BRCA-Mutated Prostate Cancer
The FDA fully authorized rucaparib for metastatic castration-resistant prostate cancer with BRCA mutations, based on confirmatory data this week. This expands options for genetically targeted therapy in advanced cases. Part of broader oncology approvals from December 15-21.
Subcutaneous RYBREVANT Approved for EGFR-Mutated NSCLC
FDA greenlit RYBREVANT FASPRO, a quicker subcutaneous amivantamab version, for existing NSCLC indications with EGFR mutations. It cuts infusion time, easing patient burden in lung cancer care. Announced in recent oncology weekly roundup.
Fam-Trastuzumab Deruxtecan Plus Pertuzumab First-Line for HER2+ Breast Cancer
FDA approved the ADC combination fam-trastuzumab deruxtecan-nxki with pertuzumab as frontline therapy for HER2-positive metastatic breast cancer, backed by DESTINY-Breast09 trial. This advances ADC use in early treatment lines. Key update from December 15-21 oncology news.
Shionogi Acquires RADICAVA Rights for ALS Treatment Expansion
Shionogi plans to acquire global rights to RADICAVA ORS and IV formulations for ALS, approved for over 20,000 US patients. The oral suspension offers easier administration than IV, with orphan exclusivity. Announced December 23, 2025, boosting rare disease portfolio.
Rabies Cases Rise in Namibia, Including Seal in Erongo
Namibia reports more rabies cases, including a seal in Erongo region as of December 19, 2025. Human and animal risks elevate in coastal areas, per ProMED alert. Calls for enhanced surveillance and vaccination.
Avian Influenza H5N1 Spreads in South Korea Poultry
South Korea confirms HPAI H5N1 in North Chungcheong poultry farms, with ongoing spread as of December 17, 2025. Culling and control measures implemented amid global bird flu concerns. ProMED monitors for human spillover risks.
FDA Approves Brensocatib for Non-CF Bronchiectasis
Brensocatib (Brinspuri) becomes the first FDA-approved treatment for non-cystic fibrosis bronchiectasis, a neutrophil-driven lung disease, based on ASPEN phase 3 trial. Tops inflammation news for 2025, transforming care for underserved patients.